|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Cholesterol Lowering and Stroke: No Longer Room for Pleiotropic Effects of Statins - Confirmation from PCSK9 Inhibitor Studies.
|
31301293 |
2020 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
In contrast, PCSK9 inhibition was associated with reductions in myocardial infarction (OR 0.80, 95% CI 0.71 to 0.91; p <0.0001), stroke (OR 0.75, 95% CI 0.65 to 0.85; p <0.0001), and coronary revascularization (OR 0.82, 95% CI 0.77 to 0.88; p <0.0001).
|
31679643 |
2019 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Both myocardial infarction and stroke were significantly reduced following the treatment with an anti-PCSK9 mAb.
|
30926528 |
2019 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
This study demonstrated that PCSK9 inhibitors could significantly reduce the risk of MACE, non-fatal MI and stroke.
|
30842207 |
2019 |
|
Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
BEFREE |
For secondary endpoints, proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK) plus statin (PCSK/ST) significantly reduced the risk of non-fatal MI (RR 0.82, 95% CI 0.72-0.93, <i>p</i> = 0.003), stroke (RR 0.74, 95% CI 0.65-0.85, <i>p</i> < 0.001), coronary revascularization (RR 0.84, 95% CI 0.75-0.94, <i>p</i> = 0.003) compared to ST.
|
31191304 |
2019 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, a novel class of monoclonal antibodies, reduce low-density lipoprotein cholesterol levels and improve outcomes of myocardial infarction and stroke.
|
30729307 |
2019 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Different phase 2 and 3 studies, including OSLER and ODYSSEY LONG-TERM, have demonstrated the efficacy and safety of the new monoclonal antibodies against PCSK9 such as evolucumab and alirocumab, and the first exploratory analyses have shown evidence of their efficacy in decreasing vascular events, including stroke.
|
28549755 |
2019 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
The individual estimated lifetime benefit from PCSK9 inhibition in patients with stable CAD on high-dose statin varied from <6 to ≥12 months free of stroke or MI.
|
29622600 |
2018 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Results In network meta-analysis of 189,116 patients, PCSK9 inhibitors were ranked as the best treatment for prevention of major adverse cardiovascular events (Surface Under Cumulative Ranking Curve (SUCRA), 85%), myocardial infarction (SUCRA, 84%) and stroke (SUCRA, 80%).
|
29569492 |
2018 |
|
Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We investigated the association between PCSK9 LOF variants and neurocognitive impairment and decline among black REGARDS study (Reasons for Geographic and Racial Differences in Stroke) participants with (n=241) and without (n=10 454) C697X or Y142X LOF variants.
|
29146683 |
2018 |
|
Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In the DIABHYCAR study, plasma PCSK9 tertiles were associated with the incidence of MI, all CV events and stroke/TIA (P for trend <.05).
|
29205760 |
2018 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
One completed cardiovascular (CV) outcomes trial (FOURIER; Further Cardiovascular Outcomes Research with PCSK9 Inhibitions in Subjects with Elevated Risk) has demonstrated that PCSK9 inhibition reduces rates of CV death as well as non-fatal stroke and MI, while another major CV outcome trial is under way (ODYSSEY-OUTCOMES).
|
28879791 |
2017 |
|
Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Polymorphisms in the proprotein convertase subtilisin/kexin type 9 (<i>PCSK9</i>) gene are associated with severe hypercholesterolemia and stroke.
|
28966647 |
2017 |
|
Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Our analysis suggests that PCSK9 inhibitors are not associated with an increased risk of cumulative severe adverse effects, musculoskeletal effects, or stroke.
|
28073851 |
2017 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
Compared with no PCSK9 inhibitor therapy, treatment with a PCSK9 inhibitor was associated with a lower rate of myocardial infarction (2.3% versus 3.6%; odds ratio [OR]: 0.72 [95% confidence interval (CI), 0.64-0.81]; <i>P</i><0.001), stroke (1.0% versus 1.4%; OR: 0.80 [95% CI, 0.67-0.96]; <i>P</i>=0.02), and coronary revascularization (4.2% versus 5.8%; OR: 0.78 [95% CI, 0.71-0.86]; <i>P</i><0.001).
|
29223954 |
2017 |
|
Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
BEFREE |
With the help of genome-wide technology, novel genetic variants have been implicated in CeVD and lipid metabolism such as those in protein convertase subtilisin/kexin type 9 (PCSK9) gene in stroke and familial hypercholesterolemia.
|
26959706 |
2016 |
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
BEFREE |
We noted that PCSK9 46L was associated with tendency for protection from myocardial infarction but not stroke suggesting a difference in the effect on susceptibility to these disorders.
|
18343176 |
2008 |
|
Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Our findings in this unique combination of clinical and autopsy data, provide evidence that PCSK9 gene associates with the risk of LVA stroke subtype, and suggest that the risk is mediated by the severity of intracranial atherosclerosis.
|
17940607 |
2007 |
|
Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
LHGDN |
Our findings in this unique combination of clinical and autopsy data, provide evidence that PCSK9 gene associates with the risk of LVA stroke subtype, and suggest that the risk is mediated by the severity of intracranial atherosclerosis.
|
17940607 |
2007 |